Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-134-VI | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.00552 | uM | 7877.007 | 1.0216 | 1.0729 | 0.5977 | |
| MDA-MB-134-VI | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.0276 | uM | 7877.007 | 1.8289 | 4.4918 | 0.5977 | |
| MDA-MB-134-VI | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.138 | uM | 7877.007 | 0.9779 | 0.9267 | 0.5977 | |
| MDA-MB-134-VI | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.69 | uM | 7877.007 | 0.8424 | 0.5011 | 0.5977 | |
| MDA-MB-134-VI | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 3.45 | uM | 7877.007 | 0.2773 | -0.7661 | 0.5977 | |
| MDA-MB-134-VI | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 17.2 | uM | 7877.007 | 0.0397 | -0.9909 | 0.5977 | |
| MDA-MB-134-VI | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 86.2 | uM | 7877.007 | 1.7181 | 3.9464 | 0.5977 | |
| MDA-MB-134-VI | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.000236 | uM | 10077.121 | 1.2117 | 1.9656 | 0.4875 | |
| MDA-MB-134-VI | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.00118 | uM | 10077.121 | 0.9307 | 0.7261 | 0.4875 | |
| MDA-MB-134-VI | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.00589 | uM | 10077.121 | 1.2051 | 1.9325 | 0.4875 | |
| MDA-MB-134-VI | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.0294 | uM | 10077.121 | 0.9863 | 0.9441 | 0.4875 | |
| MDA-MB-134-VI | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.147 | uM | 10077.121 | 1.1235 | 1.5396 | 0.4875 | |
| MDA-MB-134-VI | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.736 | uM | 10077.121 | 0.9809 | 0.9224 | 0.4875 | |
| MDA-MB-134-VI | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 3.68 | uM | 10077.121 | 0.2984 | -0.8327 | 0.4875 | |
| MDA-MB-134-VI | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 18.4 | uM | 10077.121 | 0.0874 | -0.9865 | 0.4875 | |
| MDA-MB-134-VI | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 92 | uM | 10077.121 | 0.0386 | -0.9975 | 0.4875 | |
| MDA-MB-157 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.000236 | uM | 7879.077 | 1.0561 | 1.0598 | 1.8534 | |
| MDA-MB-157 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.00118 | uM | 7879.077 | 1.0204 | 1.0219 | 1.8534 | |
| MDA-MB-157 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.00589 | uM | 7879.077 | 0.9745 | 0.9723 | 1.8534 | |
| MDA-MB-157 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.0294 | uM | 7879.077 | 0.8297 | 0.8084 | 1.8534 | |
| MDA-MB-157 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.147 | uM | 7879.077 | 0.8740 | 0.8598 | 1.8534 | |
| MDA-MB-157 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.736 | uM | 7879.077 | 0.3651 | 0.1612 | 1.8534 | |
| MDA-MB-157 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 3.68 | uM | 7879.077 | 0.0364 | -0.6653 | 1.8534 | |
| MDA-MB-157 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 18.4 | uM | 7879.077 | 0.0242 | -0.7313 | 1.8534 | |
| MDA-MB-157 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 92 | uM | 7879.077 | 0.0036 | -0.9047 | 1.8534 |